Interrogating Publicly Available Datasets for Biomarker Discovery & Prioritisation

• Presenting a worked example of how data from human cell lines and primary tumours can be leveraged to identify biomarker of response to a compound currently in clinical development
• Discussing biomarker complexity as a consideration for clinical development

Speakers:

Philip Beer

Chief Scientific Officer

Step Pharma